Clinical trial
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for…
NCT00243568 · Merck Sharp & Dohme LLC, Industry · Withdrawn
Key facts
| NCT number | NCT00243568 |
|---|---|
| Title | Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 |
| Official title | Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E2) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Acquired Immunodeficiency Syndrome |
| Intervention type | Drug |
| Interventions | Vicriviroc |
| Enrollment | 0 |
| Start date | Sep 1, 2005 |
| First posted | Oct 24, 2005 |
| Last update posted | Sep 12, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: